Bourne Lent Asset Management Inc Invitae Corp Transaction History

Bourne Lent Asset Management Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 19, 2024	BUY	$0.42 - $0.72 $83,958 - $143,928	199,900 Added 53.35%	574,600 $361,000
Q3 2023 Oct 19, 2023	BUY	$0.6 - $1.53 $12,420 - $31,671	20,700 Added 5.85%	374,700 $224,000
Q2 2023 Jul 17, 2023	BUY	$1.05 - $1.63 $84,682 - $131,459	80,650 Added 29.5%	354,000 $400,000
Q1 2023 Apr 24, 2023	BUY	$1.2 - $2.73 $98,400 - $223,860	82,000 Added 42.85%	273,350 $369,000
Q4 2022 Jan 23, 2023	SELL	$1.71 - $3.61 $21,289 - $44,944	-12,450 Reduced 6.11%	191,350 $0
Q3 2022 Oct 31, 2022	SELL	$1.9 - $8.63 $32,680 - $148,436	-17,200 Reduced 7.78%	203,800 $501,000
Q2 2022 Jul 27, 2022	BUY	$2.13 - $9.01 $43,239 - $182,903	20,300 Added 10.11%	221,000 $539,000
Q1 2022 Apr 26, 2022	BUY	$6.28 - $15.59 $533,172 - $1.32 Million	84,900 Added 73.32%	200,700 $1.6 Million
Q4 2021 Jan 20, 2022	BUY	$14.7 - $28.67 $457,170 - $891,637	31,100 Added 36.72%	115,800 $1.77 Million
Q3 2021 Oct 20, 2021	BUY	$24.31 - $33.6 $19,448 - $26,880	800 Added 0.95%	84,700 $2.41 Million
Q2 2021 Jul 28, 2021	BUY	$26.09 - $40.4 $433,094 - $670,640	16,600 Added 24.67%	83,900 $2.83 Million
Q1 2021 Apr 23, 2021	BUY	$33.06 - $56.93 $2.22 Million - $3.83 Million	67,300 New	67,300 $2.57 Million

1.92M

Ticker NVTA
Exchange NYSE
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 235,266,000
Description
Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and...

Get notified when there are updates to the investment portfolio of Bourne Lent Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Bourne Lent Asset Management Inc with notifications on news.